Project Grant K08CA313764
Award Date 9/3/26
Completion Date 8/31/31
Dollars Obligated $252K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $745,458 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a digital intervention that uses patient portals to improve person-centered communication between cancer patients and oncology clinicians. The PERSON intervention comprises three automated, scalable components: a portal-enabled assessment tool (a 14-item questionnaire capturing patient information...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $653,441 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a communication skills training program for family caregivers of patients with advanced cancer. The award funds a randomized controlled trial evaluating Communication Training for Caregivers (CT-C), a two-hour intervention that equips caregivers with skills to engage in advance care planning...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $187,037 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support adolescent and young adult enrollment in oncology clinical trials through bridging national and local trial systems. Dr. Justine Kahn, an associate professor of pediatrics and clinical trialist at Columbia University Irving Medical Center and the Herbert Irving Comprehensive Cancer Center (an...
- The National Cancer Institute awarded Sloan-Kettering Institute For Cancer Research $263,073 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research identifying genetic factors mediating alternative lengthening of telomeres (ALT) in cancer. The research targets ALT, a recombination-based telomere maintenance mechanism present in 10–15 percent of cancers, particularly sarcomas and gliomas. The investigator will conduct three aims: examining how chromatin...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $140,364 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support the K99 phase of research developing cancer survivor hospitalization risk assessment through multimodal analysis of care manager–patient communications in managed long-term care settings. The project, "The CHAMP Study: Cancer Survivor Hospitalization Risk Assessment Through Multimodal Patient-Care...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $457,252 on June 10, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test RECONJOINT, a web-based preference elicitation tool for shared decision-making in breast reconstruction surgery. The award funds development of an implementation toolkit to support clinical integration of the RECONJOINT decision tool, which uses adaptive choice-based conjoint analysis to capture...
- The National Institutes of Health National Cancer Institute awarded the Sloan-Kettering Institute For Cancer Research $731,503 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial of brief behavioral activation for older adult cancer survivors. The research addresses depression among cancer survivors aged 65 and older, a population expected to comprise 73 percent of all cancer survivors by 2040, with up to 35 percent...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $709,145 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate senescence-modulating nanoparticles targeting P-selectin on senescent cells as a strategy to potentiate cancer immunotherapy in fibrotic tumors. The project addresses a barrier in cancer immunotherapy: many patients with solid tumors remain unresponsive to immune checkpoint blockade and CAR T cell...